Nasus Pharma
Manufacturing · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
65 Yigal Alon, Tel Aviv, IsraelPhone Number
+972 35736632Website
www.nasuspharma.comRevenue
-Stock Symbol
NSRXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Nasus Pharma
Nasus Pharma specializes in developing a portfolio of powder-based intranasal products aimed at addressing acute medical conditions and public health threats. Utilizing unique microsphere technology, their products provide rapid absorption and quick drug delivery, making them suitable for emergency situations. Their intranasal therapies, including Naloxone and Epinephrine, excel in speed and effectiveness, potentially saving lives. The company targets healthcare providers and emergency response systems that require efficient drug delivery solutions in critical moments.Explore more
Nasus Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nasus Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Nasus Pharma has recently received funding, and reach out quickly before it becomes old news!
Nasus Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Nasus Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Nasus Pharma launches new products
Website visits: Recent activity has been detected on your website
Check out if Nasus Pharma is spiking on competitors!
Earning: See what the market has to say on Nasus Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Nasus Pharma
Click to see if Nasus Pharma had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Nasus Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
Nasus Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nasus Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nasus Pharma.
Nasus Pharma financials insights
Gather financial insights about Nasus Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$15M
Nasus Pharma Tech Stack
A closer look at the technologies used by Nasus Pharma
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Pharmaceuticals
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Nasus Pharma News & Media
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel.Nasus Pharma Announces Transition of Chief Financial Officer
TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company toNasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive OfficerNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady will lead the Company's next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company's pipeline
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Nasus Pharma
Sign Up For FreeTo access detailed company insights
Nasus Pharma specializes in developing a portfolio of powder-based intranasal products aimed at addressing acute medical conditions and public health threats. Utilizing unique microsphere technology, their products provide rapid absorption and quick drug delivery, making them suitable for emergency situations. Their intranasal therapies, including... Read More
